Table 1 Correlation between CMTM6/vimentin protein expression and the clinicopathological characteristics of patients with HCC (n = 90)
Features | Total number (n = 90) | Expression of CMTM6 | P-value | Expression of vimentin | P-value | ||
|---|---|---|---|---|---|---|---|
Low | High | Low | High | ||||
Age(years) | |||||||
 < 60 | 68 | 21 (30.9%) | 47 (69.1%) | 0.386 | 24 (35.3%) | 44 (64.7%) | 0.219 |
 ≥ 60 | 22 | 9 (40.9%) | 13 (59.1%) |  | 11 (50.0%) | 11 (50.0%) |  |
Gender | |||||||
 Male | 80 | 27 (33.8%) | 53 (66.3%) | 0.813 | 32 (40.0%) | 48 (60.0%) | 0.541 |
 Female | 10 | 3 (30.0%) | 7 (70.0%) |  | 3 (30.0%) | 7 (70.0%) |  |
Microvascular invasion | |||||||
 Present | 54 | 23 (42.6%) | 31 (57.4%) | 0.04* | 26 (48.1%) | 35 (51.9%) | 0.013* |
 Absent | 26 | 5 (19.2%) | 21 (80.8%) |  | 5 (19.2%) | 21 (80.8%) |  |
Tumour size(cm) | |||||||
 < 5 | 51 | 22 (43.1%) | 29 (56.9%) | 0.024* | 25 (49.0%) | 26 (51.0%) | 0.024* |
 ≥ 5 | 39 | 8 (20.5%) | 31 (79.5%) |  | 10 (25.6%) | 29 (74.4%) |  |
Differentiation | |||||||
 Well | 15 | 9 (60.0%) | 6 (40.0%) | 0.039* | 12 (80.0%) | 3 (20.0%) | 0.001* |
 Moderate | 38 | 10 (26.3%) | 28 (73.7%) |  | 11 (28.9%) | 27 (71.1%) |  |
 Poor | 31 | 8 (25.8%) | 23 (74.2%) |  | 8 (25.8%) | 23 (74.2%) |  |
HBsAg | |||||||
 Negative | 19 | 11 (57.9%) | 8 (42.1%) | 0.012* | 6 (31.6%) | 13 (68.4%) | 0.436 |
 Positive | 70 | 19 (27.1%) | 51 (72.9%) |  | 29 (41.4%) | 41 (58.6%) |  |
Serum AFP level (ng/ml) | |||||||
 < 25 | 39 | 9 (23.1%) | 30 (76.9%) | 0.061 | 16 (41.0%) | 23 (59.0%) | 0.772 |
 ≥ 25 | 50 | 21 (42.0%) | 29 (58.0%) |  | 19 (38.0%) | 31 (62.0%) |  |
TNM stage | |||||||
 I + II | 78 | 29 (37.2%) | 49 (62.8%) | 0.048* | 35 (44.9%) | 43 (55.1%) | 0.003* |
 III + IV | 12 | 1 (8.3%) | 11 (91.7%) |  | 0 (0.0%) | 12 (100.0%) |  |